- RecruitingPHASE3
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This study is for people recently diagnosed with a type of blood cancer called multiple myeloma who can't have a stem cell transplant. It compares a new medicine called AZD0120 with current standard treatments to see if it works better at controlling the cancer and keeping people well for longer.
For: Newly Diagnosed Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE1, PHASE2
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
This study is testing a new cell therapy (AZD0120) for people with AL amyloidosis that has come back or not responded to previous treatments. It aims to see how safe and effective the treatment is.
For: Relapsed AL Amyloidosis · Refractory AL Amyloidosis · Light Chain AmyloidosisUnited States · Canada · United Kingdom - RecruitingPHASE1, PHASE2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
This study is testing a new treatment called AZD0120 for severe lupus (Systemic Lupus Erythematosus) that hasn't responded to other medicines. It aims to see if the treatment is safe, how well people tolerate it, and if it helps improve lupus symptoms in adults.
For: Lupus Erythematosus, SystemicUnited States · Australia · Canada - Not yet recruitingPHASE3
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
This study looks at a new treatment called AZD0120 for people with newly diagnosed multiple myeloma. It compares AZD0120 to a standard stem cell transplant to see which is better at stopping the cancer from growing.
For: Newly Diagnosed Multiple Myeloma (NDMM)United States · Australia · Brazil - RecruitingPHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
This study compares a new treatment, AZD0120, with standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new medicine works better and is safe for patients.
For: Relapsed Refractory Multiple MyelomaUnited States · Australia · Brazil - RecruitingPHASE1
A Study of AZD0120 in Autoimmune Diseases
This study is looking at a new treatment called AZD0120 for certain long-term conditions like systemic sclerosis, inflammatory muscle diseases, and severe rheumatoid arthritis. It's an early-stage study to see how safe the treatment is and if people can tolerate it.
For: Systemic Sclerosis · Idiopathic Inflammatory Myopathies · Rheumatoid ArthritisUnited States · Australia · Germany